Overview

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR +/HER2- breast cancer patients with poor response to previous chemotherapy.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Shengjing Hospital

Treatments:

Docetaxel
Epirubicin
Exemestane
Goserelin